The purpose of this study was to evaluate the efficacy of ipriflavone in pr
eventing bone loss, decreasing in serum cholesterol and decreasing the rate
of appearance of vasomotor symptoms, as well as the effects of ipriflavone
on reduction of myoma volume by estrogen deficiency during treatment with
the GnRH analog leuprolide.
One hundred two women (mean age, 44.3 +/- . 0.53 yr) receiving leuprolide t
herapy for uterine leiomyoma were randomly allocated to two groups (group A
, leuprolide only; group B, leuprolide with ipriflavone).
Bone mineral density of the lumbar spine was measured by dual-energy x-ray
absorptiometry before and after treatment for 6 months. Levels of serum tot
al cholesterol (TC), triglyceride (TG), high-density lipoprotein cholestero
l, and low-density lipoprotein cholesterol (LDL-C) were measured before tre
atment and after 3 and 6 months of treatment. Subjects were asked to report
the appearance of vasomotor symptoms throughout treatment. Myoma node volu
mes were measured before treatment and after treatment for 6 months. Bone m
ineral density was reduced in both groups, with reduction rates of -5.26% i
n group A and -3.70% in group B (P < 0.01 vs. group A). Changes in bone mar
kers were not significant in either group. TC was significantly increased i
n both groups, and TG levels were increased significantly after 3 and 6 mon
ths of treatment in group Abut not in group B. There was no significant dif
ference between these two groups in amount of increase of either TC or TG.
LDL-C levels were increased significantly after 3 and 6 months of treatment
in both groups, and the differences between the groups (11.7% in group A v
s. 7.5% ingroup B at 3 month and 22.6% in group A us. 8.4% in group B at 6
month) were significant. Severe vasomotor symptoms were reduced in group B.
The rates of reduction of myoma volume were 49.8% in group A and 52.9% in
group B; this difference between groups was not significant.
Ipriflavone efficaciously alleviated the adverse effects of estrogen defici
ency such as bone loss and increase in LDL-C level, and the ability of leup
rolide therapy to reduce myoma volume was not decreased by ipriflavone admi
nistration.